

Published in final edited form as:

Nat Genet. 2010 November ; 42(11): 937–948. doi:10.1038/ng.686.

Association analyses of 249,796 individuals reveal eighteen new loci associated with body mass index

Elizabeth K. Speliotes^{1,2,*}, Cristen J. Willer^{3,*}, Sonja I. Berndt^{4,*}, Keri L. Monda^{5,*}, Gudmar Thorleifsson^{6,*}, Anne U. Jackson³, Hana Lango Allen⁷, Cecilia M. Lindgren^{8,9}, Jian'an Luan¹⁰, Reedik Mägi⁸, Joshua C. Randall⁸, Sailaja Vedantam^{1,11}, Thomas W. Winkler¹², Lu Qi^{13,14}, Tsegaselassie Workalemahu¹³, Iris M. Heid^{12,15}, Valgerdur Steinthorsdottir⁶, Heather M. Stringham³, Michael N. Weedon⁷, Eleanor Wheeler¹⁶, Andrew R. Wood⁷, Teresa Ferreira⁸, Robert J. Weyant³, Ayellet V. Segre^{17,18,19}, Karol Estrada^{20,21,22}, Liming Liang^{23,24}, James Nemesh¹⁸, Ju-Hyun Park⁴, Stefan Gustafsson²⁵, Tuomas O. Kilpeläinen¹⁰, Jian Yang²⁶, Nabila Bouatia-Naji^{27,28}, Tõnu Esko^{29,30,31}, Mary F. Feitosa³², Zoltán Kutalik^{33,34}, Massimo Mangino³⁵, Soumya Raychaudhuri^{18,36}, Andre Scherag³⁷, Albert Vernon Smith^{38,39}, Ryan Welch³, Jing Hua Zhao¹⁰, Katja K. Aben⁴⁰, Devin M. Absher⁴¹, Najaf Amin²⁰, Anna L. Dixon⁴², Eva Fisher⁴³, Nicole L. Glazer^{44,45}, Michael E. Goddard^{46,47}, Nancy L. Heard-Costa⁴⁸, Volker Hoesel⁴⁹, Jouke-Jan Hottenga⁵⁰, Åsa Johansson^{51,52}, Toby Johnson^{33,34,53,54}, Shamika Ketkar³², Claudia Lamina^{15,55}, Shengxu Li¹⁰, Miriam F. Moffatt⁵⁶, Richard H. Myers⁵⁷, Narisu Narisu⁵⁸, John R.B. Perry⁷, Marjolein J. Peters^{21,22}, Michael Preuss⁵⁹, Samuli Ripatti^{60,61}, Fernando Rivadeneira^{20,21,22}, Camilla Sandholt⁶², Laura J. Scott³, Nicholas J. Timpson⁶³, Jonathan P. Tyrer⁶⁴, Sophie van Wingerden²⁰, Richard M. Watanabe^{65,66}, Charles C. White⁶⁷, Fredrik Wiklund²⁵, Christina Barlassina⁶⁸, Daniel I. Chasman^{69,70}, Matthew N. Cooper⁷¹, John-Olov Jansson⁷², Robert W. Lawrence⁷¹, Niina Pellikka^{60,61}, Inga Prokopenko^{8,9}, Jianxin Shi⁴, Elisabeth Thiering¹⁵, Helene Alavere²⁹, Maria T. S. Alibrandi⁷³, Peter Almgren⁷⁴, Alice M. Arnold^{75,76}, Thor Aspelund^{38,39}, Larry D. Atwood⁴⁸, Beverley Balkau^{77,78}, Anthony J. Balmforth⁷⁹, Amanda J. Bennett⁹, Yoav Ben-Shlomo⁸⁰, Richard N. Bergman⁶⁶, Sven Bergmann^{33,34}, Heike Biebermann⁸¹, Alexandra I.F. Blakemore⁸², Tanja Boes³⁷, Lori L. Bonnycastle⁵⁸, Stefan R. Bornstein⁸³, Morris J. Brown⁸⁴, Thomas A. Buchanan^{66,85}, Fabio Busonero⁸⁶, Harry Campbell⁸⁷, Francesco P. Cappuccio⁸⁸, Christine Cavalcanti-Proença^{27,28}, Yii-Der Ida Chen⁸⁹, Chih-Mei Chen¹⁵, Peter S. Chines⁵⁸, Robert Clarke⁹⁰, Lachlan Coin⁹¹, John Connell⁹², Ian N.M. Day⁶³, Martin den Heijer^{93,94}, Jubao Duan⁹⁵, Shah Ebrahim^{96,97}, Paul Elliott^{91,98}, Roberto Elosua⁹⁹, Gudny Eiriksdottir³⁸, Michael R. Erdos⁵⁸, Johan G. Eriksson^{100,101,102,103,104}, Maurizio F. Facheris^{105,106}, Stephan B. Felix¹⁰⁷, Pamela Fischer-Posovszky¹⁰⁸, Aaron R. Folsom¹⁰⁹, Nele Friedrich¹¹⁰, Nelson B. Freimer¹¹¹, Mao Fu¹¹², Stefan Gaget^{27,28}, Pablo V. Gejman⁹⁵, Eco J.C. Geus⁵⁰, Christian Gieger¹⁵, Anette P. Gjesing⁶², Anuj Goel^{8,113}, Philippe Goyette¹¹⁴, Harald Grallert¹⁵, Jürgen Gräßler¹¹⁵, Danielle M. Greenawalt¹¹⁶, Christopher J. Groves⁹, Vilmundur Gudnason^{38,39}, Candace Guiducci¹, Anna-Liisa Hartikainen¹¹⁷, Neelam Hassanali⁹, Alistair S. Hall⁷⁹, Aki S.

Users may view, print, copy, download and text and data- mine the content in such documents, for the purposes of academic research, subject always to the full Conditions of use: http://www.nature.com/authors/editorial_policies/license.html#terms

Correspondence should be addressed to Michael Boehnke (boehnke@umich.edu), Kari Stefansson (kstefans@decode.is), Kari North (kari_north@unc.edu), Mark McCarthy (mark.mccarthy@dr1.ox.ac.uk), Joel Hirschhorn (joelh@broadinstitute.org), Erik Ingelsson (erik.ingelsson@ki.se), and Ruth Loos (ruth.loos@mrc-epid.cam.ac.uk).

*These authors contributed equally to this work.

Author contributions

A full list of author contributions appears in the Supplementary Note.

Competing interests statement

The authors declare competing financial interests. A full list of competing interests appears in the Supplementary Note.

Havulinna¹¹⁸, Caroline Hayward¹¹⁹, Andrew C. Heath¹²⁰, Christian Hengstenberg^{121,122}, Andrew A. Hicks¹⁰⁵, Anke Hinney¹²³, Albert Hofman^{20,22}, Georg Homuth¹²⁴, Jennie Hui^{71,125,126}, Wilmar Igl⁵¹, Carlos Iribarren^{127,128}, Bo Isomaa^{103,129}, Kevin B. Jacobs¹³⁰, Ivonne Jarick¹³¹, Elizabeth Jewell³, Ulrich John¹³², Torben Jørgensen^{133,134}, Pekka Jousilahti¹¹⁸, Antti Jula¹³⁵, Marika Kaakinen^{136,137}, Eero Kajantie^{101,138}, Lee M. Kaplan^{2,70,139}, Sekar Kathiresan^{17,18,140,141,142}, Johannes Kettunen^{60,61}, Leena Kinnunen¹⁴³, Joshua W. Knowles¹⁴⁴, Ivana Kolcic¹⁴⁵, Inke R. König⁵⁹, Seppo Koskinen¹¹⁸, Peter Kovacs¹⁴⁶, Johanna Kuusisto¹⁴⁷, Peter Kraft^{23,24}, Kirsti Kvaløy¹⁴⁸, Jaana Laitinen¹⁴⁹, Olivier Lantieri¹⁵⁰, Chiara Lanzani⁷³, Lenore J. Launer¹⁵¹, Cecile Lecoeur^{27,28}, Terho Lehtimäki¹⁵², Guillaume Lettre^{114,153}, Jianjun Liu¹⁵⁴, Marja-Liisa Lokki¹⁵⁵, Mattias Lorentzon¹⁵⁶, Robert N. Luben¹⁵⁷, Barbara Ludwig⁸³, MAGIC¹⁵⁸, Paolo Manunta⁷³, Diana Marek^{33,34}, Michel Marre^{159,160}, Nicholas G. Martin¹⁶¹, Wendy L. McArdle¹⁶², Anne McCarthy¹⁶³, Barbara McKnight⁷⁵, Thomas Meitinger^{164,165}, Olle Melander¹⁶⁶, David Meyre^{27,28}, Kristian Midthjell¹⁴⁸, Grant W. Montgomery¹⁶⁷, Mario A. Morcken⁵⁸, Andrew P. Morris⁸, Rosanda Mulic¹⁶⁸, Julius S. Ngwa⁶⁷, Mari Nelis^{29,30,31}, Matt J. Neville⁹, Dale R. Nyholt¹⁶⁹, Christopher J. O'Donnell^{141,170}, Stephen O'Rahilly¹⁷¹, Ken K. Ong¹⁰, Ben Oostra¹⁷², Guillaume Paré¹⁷³, Alex N. Parker¹⁷⁴, Markus Perola^{60,61}, Irene Pichler¹⁰⁵, Kirsi H. Pietiläinen^{175,176}, Carl G.P. Platou^{148,177}, Ozren Polasek^{145,178}, Anneli Pouta^{117,179}, Suzanne Rafelt¹⁸⁰, Olli Raitakari^{181,182}, Nigel W. Rayner^{8,9}, Martin Ridderstråle¹⁶⁶, Winfried Rief¹⁸³, Aimo Ruukonen¹⁸⁴, Neil R. Robertson^{8,9}, Peter Rzehak^{15,185}, Veikko Salomaa¹¹⁸, Alan R. Sanders⁹⁵, Manjinder S. Sandhu^{10,16,157}, Serena Sanna⁸⁶, Jouko Saramies¹⁸⁶, Markku J. Savolainen¹⁸⁷, Susann Scherag¹²³, Sabine Schipf^{110,188}, Stefan Schreiber¹⁸⁹, Heribert Schunkert¹⁹⁰, Kaisa Silander^{60,61}, Juha Sinisalo¹⁹¹, David S. Siscovick^{45,192}, Jan H. Smit¹⁹³, Nicole Soranzo^{16,35}, Ulla Sovio⁹¹, Jonathan Stephens^{194,195}, Ida Surakka^{60,61}, Amy J. Swift⁵⁸, Mari-Liis Tammesoo²⁹, Jean-Claude Tardif^{114,153}, Maris Teder-Laving^{30,31}, Tanya M. Teslovich³, John R. Thompson^{196,197}, Brian Thomson¹, Anke Tönjes^{198,199}, Tiinamaija Tuomi^{103,200,201}, Joyce B.J. van Meurs^{20,21,22}, Gert-Jan van Ommen^{202,203}, Vincent Vatin^{27,28}, Jorma Viikari²⁰⁴, Sophie Visvikis-Siest²⁰⁵, Veronique Vitart¹¹⁹, Carla I. G. Vogel¹²³, Benjamin F. Voight^{17,18,19}, Lindsay L. Waite⁴¹, Henri Wallaschofski¹¹⁰, G. Bragi Walters⁶, Elisabeth Widen⁶⁰, Susanna Wiegand⁸¹, Sarah H. Wild⁸⁷, Gonneke Willemsen⁵⁰, Daniel R. Witte²⁰⁶, Jacqueline C. Witteman^{20,22}, Jianfeng Xu²⁰⁷, Qunyuan Zhang³², Lina Zgaga¹⁴⁵, Andreas Ziegler⁵⁹, Paavo Zitting²⁰⁸, John P. Beilby^{125,126,209}, I. Sadaf Farooqi¹⁷¹, Johannes Hebebrand¹²³, Heikki V. Huikuri^{210,210}, Alan L. James^{126,211}, Mika Kähönen²¹², Douglas F. Levinson²¹³, Fabio Macciardi^{68,214}, Markku S. Nieminen^{191,191}, Claes Ohlsson¹⁵⁶, Lyle J. Palmer^{71,126}, Paul M. Ridker^{69,70}, Michael Stumvoll^{198,215}, Jacques S. Beckmann^{33,216}, Heiner Boeing⁴³, Eric Boerwinkle²¹⁷, Dorret I. Boomsma⁵⁰, Mark J. Caulfield⁵⁴, Stephen J. Chanock⁴, Francis S. Collins⁵⁸, L. Adrienne Cupples⁶⁷, George Davey Smith⁶³, Jeanette Erdmann¹⁹⁰, Philippe Froguel^{27,28,82}, Henrik Grönberg²⁵, Ulf Gyllenstein⁵¹, Per Hall²⁵, Torben Hansen^{62,218}, Tamara B. Harris¹⁵¹, Andrew T. Hattersley⁷, Richard B. Hayes²¹⁹, Joachim Heinrich¹⁵, Frank B. Hu^{13,14,23}, Kristian Hveem¹⁴⁸, Thomas Illig¹⁵, Marjo-Riitta Jarvelin^{91,136,137,179}, Jaakko Kaprio^{60,175,220}, Fredrik Karpe^{9,221}, Kay-Tee Khaw¹⁵⁷, Lambertus A. Kiemeny^{40,93,222}, Heiko Krude⁸¹, Markku Laakso¹⁴⁷, Debbie A. Lawlor⁶³, Andres Metspalu^{29,30,31}, Patricia B. Munroe⁵⁴, Willem H. Ouwehand^{16,194,195}, Oluf Pedersen^{62,223,224}, Brenda W. Penninx^{193,225,226}, Annette Peters¹⁵, Peter P. Pramstaller^{105,106,227}, Thomas Quertermous¹⁴⁴, Thomas Reinehr²²⁸, Aila Rissanen¹⁷⁶, Igor Rudan^{87,168}, Nilesh J. Samani^{180,196}, Peter E.H. Schwarz²²⁹, Alan R. Shuldiner^{112,230}, Timothy D. Spector³⁵, Jaakko Tuomilehto^{143,231,232}, Manuela Uda⁸⁶, André Uitterlinden^{20,21,22}, Timo T. Valle¹⁴³, Martin Wabitsch¹⁰⁸, Gérard Waeber²³³, Nicholas J. Wareham¹⁰, Hugh Watkins^{8,113}, James F. Wilson⁸⁷, Alan F. Wright¹¹⁹, M. Carola Zillikens^{21,22}, Nilanjan Chatterjee⁴, Steven A. McCarroll^{17,18,19}, Shaun Purcell^{17,234,235}, Eric E. Schadt^{236,237}, Peter M. Visscher²⁶, Themistocles L. Assimes¹⁴⁴, Ingrid B. Borecki^{32,238}, Panos Deloukas¹⁶, Caroline S. Fox²³⁹, Leif C. Groop⁷⁴, Talin Haritunians⁸⁹, David J. Hunter^{13,14,23}, Robert C. Kaplan²⁴⁰, Karen L. Mohlke²⁴¹, Jeffrey R. O'Connell¹¹², Leena

Peltonen^{16,60,61,234,242}, **David Schlessinger**²⁴³, **David P. Strachan**²⁴⁴, **Cornelia M. van Duijn**^{20,22}, **H-Erich Wichmann**^{15,185,245}, **Timothy M. Frayling**⁷, **Unnur Thorsteinsdottir**^{6,246}, **Gonçalo R. Abecasis**³, **Inês Barroso**^{16,247}, **Michael Boehnke**^{3,*}, **Kari Stefansson**^{6,246,*}, **Kari E. North**^{5,248,*}, **Mark I. McCarthy**^{8,9,221,*}, **Joel N. Hirschhorn**^{1,11,249,*}, **Erik Ingelsson**^{25,*}, and **Ruth J.F. Loos**^{10,*} on behalf of Procardis Consortium

¹ Metabolism Initiative and Program in Medical and Population Genetics, Broad Institute, Cambridge, Massachusetts 02142, USA ² Division of Gastroenterology, Massachusetts General Hospital, Boston, Massachusetts 02114, USA ³ Department of Biostatistics, Center for Statistical Genetics, University of Michigan, Ann Arbor, Michigan 48109, USA ⁴ Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Department of Health and Human Services, Bethesda, Maryland 20892, USA ⁵ Department of Epidemiology, School of Public Health, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27514, USA ⁶ deCODE Genetics, 101 Reykjavik, Iceland ⁷ Genetics of Complex Traits, Peninsula College of Medicine and Dentistry, University of Exeter, Exeter, EX1 2LU, UK ⁸ Wellcome Trust Centre for Human Genetics, University of Oxford, Oxford, OX3 7BN, UK ⁹ Oxford Centre for Diabetes, Endocrinology and Metabolism, University of Oxford, Oxford, OX3 7LJ, UK ¹⁰ MRC Epidemiology Unit, Institute of Metabolic Science, Addenbrooke's Hospital, Cambridge, CB2 0QQ, UK ¹¹ Divisions of Genetics and Endocrinology and Program in Genomics, Children's Hospital, Boston, Massachusetts 02115, USA ¹² Regensburg University Medical Center, Department of Epidemiology and Preventive Medicine, 93053 Regensburg, Germany ¹³ Department of Nutrition, Harvard School of Public Health, Boston, Massachusetts 02115, USA ¹⁴ Channing Laboratory, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts 02115, USA ¹⁵ Institute of Epidemiology, Helmholtz Zentrum München - German Research Center for Environmental Health, 85764 Neuherberg, Germany ¹⁶ Wellcome Trust Sanger Institute, Hinxton, Cambridge, CB10 1SA, UK ¹⁷ Center for Human Genetic Research, Massachusetts General Hospital, Boston, Massachusetts 02114, USA ¹⁸ Program in Medical and Population Genetics, Broad Institute of Harvard and Massachusetts Institute of Technology, Cambridge, Massachusetts 02142, USA ¹⁹ Department of Molecular Biology, Massachusetts General Hospital, Boston, Massachusetts 02114, USA ²⁰ Department of Epidemiology, Erasmus MC, Rotterdam, 3015GE, The Netherlands ²¹ Department of Internal Medicine, Erasmus MC, Rotterdam, 3015GE, The Netherlands ²² Netherlands Genomics Initiative (NGI)-sponsored Netherlands Consortium for Healthy Aging (NCHA) ²³ Department of Epidemiology, Harvard School of Public Health, Boston, Massachusetts 02115, USA ²⁴ Department of Biostatistics, Harvard School of Public Health, Boston, Massachusetts 02115, USA ²⁵ Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, 171 77 Stockholm, Sweden ²⁶ Queensland Statistical Genetics Laboratory, Queensland Institute of Medical Research, Queensland 4006, Australia ²⁷ CNRS UMR8199-IBL-Institut Pasteur de Lille, F-59019 Lille, France ²⁸ University Lille Nord de France, 59000 Lille, France ²⁹ Estonian Genome Center, University of Tartu, Tartu 50410, Estonia ³⁰ Estonian Biocenter, Tartu 51010, Estonia ³¹ Institute of Molecular and Cell Biology, University of Tartu, Tartu 51010, Estonia ³² Department of Genetics, Washington University School of Medicine, St Louis, Missouri 63110, USA ³³ Department of Medical Genetics, University of Lausanne, 1005 Lausanne, Switzerland ³⁴ Swiss Institute of Bioinformatics, 1015 Lausanne, Switzerland ³⁵ Department of Twin Research and Genetic Epidemiology, King's College London, London, SE1 7EH, UK ³⁶ Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts 02115 USA ³⁷ Institute for Medical Informatics, Biometry and Epidemiology, University of Duisburg-Essen, 45122 Essen, Germany ³⁸ Icelandic Heart Association, Kopavogur, Iceland ³⁹ University of Iceland, Reykjavik, Iceland ⁴⁰ Comprehensive Cancer Center East, 6501 BG Nijmegen, The Netherlands ⁴¹ Hudson Alpha Institute for Biotechnology, Huntsville, Alabama 35806, USA ⁴² Department of Pharmacy and Pharmacology, University of Bath, Bath, BA1 1RL, UK ⁴³ Department of Epidemiology, German Institute of

Human Nutrition Potsdam-Rehbruecke, 14558 Nuthetal, Germany ⁴⁴ Department of Medicine, University of Washington, Seattle, Washington 98101, USA ⁴⁵ Cardiovascular Health Research Unit, University of Washington, Seattle, Washington 98101, USA ⁴⁶ University of Melbourne, Parkville 3010, Australia ⁴⁷ Department of Primary Industries, Melbourne, Victoria 3001, Australia ⁴⁸ Department of Neurology, Boston University School of Medicine, Boston, Massachusetts 02118, USA ⁴⁹ Technical University Munich, Chair of Biomathematics, Boltzmannstrasse 3, 85748 Garching ⁵⁰ Department of Biological Psychology, VU University Amsterdam, 1081 BT Amsterdam, The Netherlands ⁵¹ Department of Genetics and Pathology, Rudbeck Laboratory, University of Uppsala, SE-75185 Uppsala, Sweden ⁵² Department of Cancer Research and Molecular Medicine, Faculty of Medicine, Norwegian University of Science and Technology (NTNU), Trondheim, N-7489, Norway ⁵³ Clinical Pharmacology, William Harvey Research Institute, Barts and The London School of Medicine and Dentistry, Queen Mary, University of London, London, UK ⁵⁴ Clinical Pharmacology and Barts and The London Genome Centre, William Harvey Research Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, Charterhouse Square, London EC1M 6BQ, UK ⁵⁵ Division of Genetic Epidemiology, Department of Medical Genetics, Molecular and Clinical Pharmacology, Innsbruck Medical University, 6020 Innsbruck, Austria ⁵⁶ National Heart and Lung Institute, Imperial College London, London SW3 6LY, UK ⁵⁷ Department of Neurology, Boston University School of Medicine, Boston, Massachusetts 02118, USA ⁵⁸ National Human Genome Research Institute, National Institutes of Health, Bethesda, Maryland 20892, USA ⁵⁹ Institut für Medizinische Biometrie und Statistik, Universität zu Lubeck, Universitätsklinikum Schleswig-Holstein, Campus Lubeck, 23562 Lubeck, Germany ⁶⁰ Institute for Molecular Medicine Finland (FIMM), University of Helsinki, 00014, Helsinki, Finland ⁶¹ National Institute for Health and Welfare, Department of Chronic Disease Prevention, Unit of Public Health Genomics, 00014, Helsinki, Finland ⁶² Hagedorn Research Institute, 2820 Gentofte, Denmark ⁶³ MRC Centre for Causal Analyses in Translational Epidemiology, Department of Social Medicine, Oakfield House, Bristol, BS8 2BN, UK ⁶⁴ Department of Oncology, University of Cambridge, Cambridge, CB1 8RN, UK ⁶⁵ Department of Preventive Medicine, Keck School of Medicine, University of Southern California, Los Angeles, California 90089, USA ⁶⁶ Department of Physiology and Biophysics, Keck School of Medicine, University of Southern California, Los Angeles, California 90033, USA ⁶⁷ Department of Biostatistics, Boston University School of Public Health, Boston, Massachusetts 02118, USA ⁶⁸ University of Milan, Department of Medicine, Surgery and Dentistry, 20139 Milano, Italy ⁶⁹ Division of Preventive Medicine, Brigham and Women's Hospital, Boston, Massachusetts 02215, USA ⁷⁰ Harvard Medical School, Boston, Massachusetts 02115, USA ⁷¹ Centre for Genetic Epidemiology and Biostatistics, University of Western Australia, Crawley, Western Australia 6009, Australia ⁷² Department of Physiology, Institute of Neuroscience and Physiology, Sahlgrenska Academy, University of Gothenburg, 405 30 Gothenburg, Sweden ⁷³ University Vita-Salute San Raffaele, Division of Nephrology and Dialysis, 20132 Milan, Italy ⁷⁴ Lund University Diabetes Centre, Department of Clinical Sciences, Lund University, 20502 Malmö, Sweden ⁷⁵ Departments of Biostatistics, University of Washington, Seattle, Washington 98195, USA ⁷⁶ Collaborative Health Studies Coordinating Center, Seattle, Washington 98115, USA ⁷⁷ INSERM CESP Centre for Research in Epidemiology and Public Health U1018, Epidemiology of diabetes, obesity and chronic kidney disease over the lifecourse, 94807 Villejuif, France ⁷⁸ University Paris Sud 11, UMRS 1018, 94807 Villejuif, France ⁷⁹ Multidisciplinary Cardiovascular Research Centre (MCRC), Leeds Institute of Genetics, Health and Therapeutics (LIGHT), University of Leeds, Leeds LS2 9JT, UK ⁸⁰ Department of Social Medicine, University of Bristol, Bristol, BS8 2PS, UK ⁸¹ Institute of Experimental Paediatric Endocrinology, Charite Universitätsmedizin Berlin, 13353 Berlin, Germany ⁸² Department of Genomics of Common Disease, School of Public Health, Imperial College London, W12 0NN, London, UK ⁸³ Department of Medicine III, University of Dresden, 01307 Dresden, Germany ⁸⁴ Clinical Pharmacology Unit, University of Cambridge, Addenbrooke's Hospital, Hills Road, Cambridge CB2 2QQ, UK ⁸⁵ Division of Endocrinology, Keck

School of Medicine, University of Southern California, Los Angeles, California 90033, USA ⁸⁶
 Istituto di Neurogenetica e Neurofarmacologia del CNR, Monserrato, 09042, Cagliari, Italy ⁸⁷
 Centre for Population Health Sciences, University of Edinburgh, Teviot Place, Edinburgh, EH8
 9AG, Scotland ⁸⁸ University of Warwick, Warwick Medical School, Coventry, CV2 2DX, UK ⁸⁹
 Medical Genetics Institute, Cedars-Sinai Medical Center, Los Angeles, California 90048, USA ⁹⁰
 Clinical Trial Service Unit, Richard Doll Building, Old Road Campus, Roosevelt Drive, Oxford,
 OX3 7LF, UK ⁹¹ Department of Epidemiology and Biostatistics, School of Public Health, Faculty of
 Medicine, Imperial College London, London, W2 1PG, UK ⁹² University of Dundee, Ninewells
 Hospital & Medical School, Dundee, DD1 9SY, UK ⁹³ Department of Epidemiology, Biostatistics
 and HTA, Radboud University Nijmegen Medical Centre, 6500 HB Nijmegen, The Netherlands ⁹⁴
 Department of Endocrinology, Radboud University Nijmegen Medical Centre, 6500 HB Nijmegen,
 The Netherlands ⁹⁵ Northshore University Healthsystem, Evanston, Illinois 60201, USA ⁹⁶ The
 London School of Hygiene and Tropical Medicine, London, WC1E 7HT, UK ⁹⁷ South Asia
 Network for Chronic Disease ⁹⁸ MRC-HPA Centre for Environment and Health, London W2 1PG,
 UK ⁹⁹ Cardiovascular Epidemiology and Genetics, Institut Municipal D'investigacio Medica and
 CIBER Epidemiologia y Salud Publica, Barcelona, Spain ¹⁰⁰ Department of General Practice and
 Primary health Care, University of Helsinki, Helsinki, Finland ¹⁰¹ National Institute for Health and
 Welfare, 00271 Helsinki, Finland ¹⁰² Helsinki University Central Hospital, Unit of General Practice,
 00280 Helsinki, Finland ¹⁰³ Folkhalsan Research Centre, 00250 Helsinki, Finland ¹⁰⁴ Vasa
 Central Hospital, 65130 Vasa, Finland ¹⁰⁵ Institute of Genetic Medicine, European Academy
 Bozen/Bolzano (EURAC), Bolzano/Bozen, 39100, Italy. Affiliated Institute of the University of
 Lubeck, Lubeck, Germany ¹⁰⁶ Department of Neurology, General Central Hospital, Bolzano, Italy
¹⁰⁷ Department of Internal Medicine B, Ernst-Moritz-Arndt University, 17475 Greifswald, Germany
¹⁰⁸ Pediatric Endocrinology, Diabetes and Obesity Unit, Department of Pediatrics and Adolescent
 Medicine, 89075 Ulm, Germany ¹⁰⁹ Division of Epidemiology and Community Health, School of
 Public Health, University of Minnesota, Minneapolis Minnesota 55454, USA ¹¹⁰ Institut für
 Klinische Chemie und Laboratoriumsmedizin, Universität Greifswald, 17475 Greifswald, Germany
¹¹¹ Center for Neurobehavioral Genetics, University of California, Los Angeles, California 90095,
 USA ¹¹² Department of Medicine, University of Maryland School of Medicine, Baltimore, Maryland
 21201, USA ¹¹³ Department of Cardiovascular Medicine, University of Oxford, Level 6 West Wing,
 John Radcliffe Hospital, Headley Way, Headington, Oxford, OX3 9DU ¹¹⁴ Montreal Heart Institute,
 Montreal, Quebec, H1T 1C8, Canada ¹¹⁵ Department of Medicine III, Pathobiochemistry,
 University of Dresden, 01307 Dresden, Germany ¹¹⁶ Merck Research Laboratories, Merck & Co.,
 Inc., Boston, Massachusetts 02115, USA ¹¹⁷ Department of Clinical Sciences/Obstetrics and
 Gynecology, University of Oulu, 90014 Oulu, Finland ¹¹⁸ National Institute for Health and Welfare,
 Department of Chronic Disease Prevention, Chronic Disease Epidemiology and Prevention Unit,
 00014, Helsinki, Finland ¹¹⁹ MRC Human Genetics Unit, Institute for Genetics and Molecular
 Medicine, Western General Hospital, Edinburgh, EH4 2XU, Scotland, UK ¹²⁰ Department of
 Psychiatry and Midwest Alcoholism Research Center, Washington University School of Medicine,
 St Louis, Missouri 63108, USA ¹²¹ Klinik und Poliklinik für Innere Medizin II, Universität
 Regensburg, 93053 Regensburg, Germany ¹²² Regensburg University Medical Center, Innere
 Medizin II, 93053 Regensburg, Germany ¹²³ Department of Child and Adolescent Psychiatry,
 University of Duisburg-Essen, 45147 Essen, Germany ¹²⁴ Interfaculty Institute for Genetics and
 Functional Genomics, Ernst-Moritz-Arndt-Universität Greifswald, 17487 Greifswald, Germany ¹²⁵
 PathWest Laboratory of Western Australia, Department of Molecular Genetics, J Block, QEII
 Medical Centre, Nedlands, Western Australia 6009, Australia ¹²⁶ Busselton Population Medical
 Research Foundation Inc., Sir Charles Gairdner Hospital, Nedlands, Western Australia 6009,
 Australia ¹²⁷ Division of Research, Kaiser Permanente Northern California, Oakland, California
 94612, USA ¹²⁸ Department of Epidemiology and Biostatistics, University of California, San
 Francisco, San Francisco, California 94107, USA ¹²⁹ Department of Social Services and Health
 Care, 68601 Jakobstad, Finland ¹³⁰ Core Genotyping Facility, SAIC-Frederick, Inc., NCI-

Frederick, Frederick, Maryland 21702, USA ¹³¹ Institute of Medical Biometry and Epidemiology, University of Marburg, 35037 Marburg, Germany ¹³² Institut für Epidemiologie und Sozialmedizin, Universität Greifswald, 17475 Greifswald, Germany ¹³³ Research Centre for Prevention and Health, Glostrup University Hospital, 2600 Glostrup, Denmark ¹³⁴ Faculty of Health Science, University of Copenhagen, 2100 Copenhagen, Denmark ¹³⁵ National Institute for Health and Welfare, Department of Chronic Disease Prevention, Population Studies Unit, 20720 Turku, Finland ¹³⁶ Institute of Health Sciences, University of Oulu, 90014 Oulu, Finland ¹³⁷ Biocenter Oulu, University of Oulu, 90014 Oulu, Finland ¹³⁸ Hospital for Children and Adolescents, Helsinki University Central Hospital and University of Helsinki, 00029 HUS, Finland ¹³⁹ MGH Weight Center, Massachusetts General Hospital, Boston, Massachusetts 02114, USA ¹⁴⁰ Cardiovascular Research Center and Cardiology Division, Massachusetts General Hospital, Boston, Massachusetts 02114, USA ¹⁴¹ Framingham Heart Study of the National, Heart, Lung, and Blood Institute and Boston University, Framingham, Massachusetts 01702, USA ¹⁴² Department of Medicine, Harvard Medical School, Boston, Massachusetts 02115, USA ¹⁴³ National Institute for Health and Welfare, Diabetes Prevention Unit, 00271 Helsinki, Finland ¹⁴⁴ Department of Medicine, Stanford University School of Medicine, Stanford, California 94305, USA ¹⁴⁵ Andrija Stampar School of Public Health, Medical School, University of Zagreb, 10000 Zagreb, Croatia ¹⁴⁶ Interdisciplinary Centre for Clinical Research, University of Leipzig, 04103 Leipzig, Germany ¹⁴⁷ Department of Medicine, University of Kuopio and Kuopio University Hospital, 70210 Kuopio, Finland ¹⁴⁸ HUNT Research Centre, Department of Public Health and General Practice, Norwegian University of Science and Technology, 7600 Levanger, Norway ¹⁴⁹ Finnish Institute of Occupational Health, 90220 Oulu, Finland ¹⁵⁰ Institut inter-régional pour la santé (IRSA), F-37521 La Riche, France ¹⁵¹ Laboratory of Epidemiology, Demography, Biometry, National Institute on Aging, National Institutes of Health, Bethesda, Maryland 20892, USA ¹⁵² Department of Clinical Chemistry, University of Tampere and Tampere University Hospital, 33520 Tampere, Finland ¹⁵³ Department of Medicine, Université de Montréal, Montréal, Québec, H3T 1J4, Canada ¹⁵⁴ Human Genetics, Genome Institute of Singapore, Singapore 138672, Singapore ¹⁵⁵ Transplantation Laboratory, Haartman Institute, University of Helsinki, 00014, Helsinki, Finland ¹⁵⁶ Department of Internal Medicine, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, 413 45 Gothenburg, Sweden ¹⁵⁷ Department of Public Health and Primary Care, Institute of Public Health, University of Cambridge, Cambridge CB2 2SR, UK ¹⁵⁸ On behalf of the MAGIC (Meta-Analyses of Glucose and Insulin-related traits Consortium) investigators ¹⁵⁹ Department of Endocrinology, Diabetology and Nutrition, Bichat-Claude Bernard University Hospital, Assistance Publique des Hôpitaux de Paris, F-75018 Paris, France ¹⁶⁰ Cardiovascular Genetics Research Unit, Université Henri Poincaré-Nancy 1, 54000, Nancy, France ¹⁶¹ Genetic Epidemiology Laboratory, Queensland Institute of Medical Research, Queensland 4006, Australia ¹⁶² Avon Longitudinal Study of Parents and Children (ALSPAC) Laboratory, Department of Social Medicine, University of Bristol, Bristol, BS8 2BN, UK ¹⁶³ Division of Health, Research Board, An Bord Teaghde Slainte, Dublin, 2, Ireland ¹⁶⁴ Institute of Human Genetics, Klinikum rechts der Isar der Technischen Universität München, 81675 Munich, Germany ¹⁶⁵ Institute of Human Genetics, Helmholtz Zentrum München - German Research Center for Environmental Health, 85764 Neuherberg, Germany ¹⁶⁶ Department of Clinical Sciences, Lund University, 20502 Malmö, Sweden ¹⁶⁷ Molecular Epidemiology Laboratory, Queensland Institute of Medical Research, Queensland 4006, Australia ¹⁶⁸ Croatian Centre for Global Health, School of Medicine, University of Split, Split 21000, Croatia ¹⁶⁹ Neurogenetics Laboratory, Queensland Institute of Medical Research, Queensland 4006, Australia ¹⁷⁰ National, Lung, and Blood Institute, National Institutes of Health, Framingham, Massachusetts 01702, USA ¹⁷¹ University of Cambridge Metabolic Research Laboratories, Institute of Metabolic Science, Addenbrooke's Hospital, Cambridge CB2 0QQ, UK ¹⁷² Department of Clinical Genetics, Erasmus MC, Rotterdam, 3015GE, The Netherlands ¹⁷³ Department of Pathology and Molecular Medicine, McMaster University, Hamilton, Ontario L8N3Z5, Canada ¹⁷⁴ Amgen, Cambridge, Massachusetts 02139, USA ¹⁷⁵

Finnish Twin Cohort Study, Department of Public Health, University of Helsinki, 00014, Helsinki, Finland ¹⁷⁶ Obesity Research unit, Department of Psychiatry, Helsinki University Central Hospital, Helsinki, Finland ¹⁷⁷ Department of Medicine, Levanger Hospital, The Nord-Trøndelag Health Trust, 7600 Levanger, Norway ¹⁷⁸ Gen-Info Ltd, 10000 Zagreb, Croatia ¹⁷⁹ National Institute for Health and Welfare, 90101 Oulu, Finland ¹⁸⁰ Department of Cardiovascular Sciences, University of Leicester, Glenfield Hospital, Leicester, LE3 9QP, UK ¹⁸¹ Research Centre of Applied and Preventive Cardiovascular Medicine, University of Turku, 20520 Turku, Finland ¹⁸² The Department of Clinical Physiology, Turku University Hospital, 20520 Turku, Finland ¹⁸³ Clinical Psychology and Psychotherapy, University of Marburg, 35032 Marburg, Germany ¹⁸⁴ Department of Clinical Sciences/Clinical Chemistry, University of Oulu, 90014 Oulu, Finland ¹⁸⁵ Ludwig-Maximilians-Universität, Institute of Medical Informatics, Biometry and Epidemiology, Chair of Epidemiology, 81377 Munich, Germany ¹⁸⁶ South Karelia Central Hospital, 53130 Lappeenranta, Finland ¹⁸⁷ Department of Clinical Sciences/Internal Medicine, University of Oulu, 90014 Oulu, Finland ¹⁸⁸ Institut für Community Medicine, 17489 Greifswald, Germany ¹⁸⁹ Christian-Albrechts-University, University Hospital Schleswig-Holstein, Institute for Clinical Molecular Biology and Department of Internal Medicine I, 24105 Kiel, Germany ¹⁹⁰ Universität zu Lübeck, Medizinische Klinik II, 23562 Lübeck, Germany ¹⁹¹ Division of Cardiology, Cardiovascular Laboratory, Helsinki University Central Hospital, 00029 Helsinki, Finland ¹⁹² Departments of Medicine and Epidemiology, University of Washington, Seattle, Washington 98195, USA ¹⁹³ Department of Psychiatry/EMGO Institute, VU University Medical Center, 1081 BT Amsterdam, The Netherlands ¹⁹⁴ Department of Haematology, University of Cambridge, Cambridge CB2 0PT, UK ¹⁹⁵ NHS Blood and Transplant, Cambridge Centre, Cambridge, CB2 0PT, UK ¹⁹⁶ Leicester NIHR Biomedical Research Unit in Cardiovascular Disease, Glenfield Hospital, Leicester, LE3 9QP, UK ¹⁹⁷ Department of Health Sciences, University of Leicester, University Road, Leicester, LE1 7RH, UK ¹⁹⁸ Department of Medicine, University of Leipzig, 04103 Leipzig, Germany ¹⁹⁹ Coordination Centre for Clinical Trials, University of Leipzig, Härtelstr. 16-18, 04103 Leipzig, Germany ²⁰⁰ Department of Medicine, Helsinki University Central Hospital, 00290 Helsinki, Finland ²⁰¹ Research Program of Molecular Medicine, University of Helsinki, 00014 Helsinki, Finland ²⁰² Department of Human Genetics, Leiden University Medical Center, 2333 ZC Leiden, the Netherlands ²⁰³ Center of Medical Systems Biology, Leiden University Medical Center, 2333 ZC Leiden, the Netherlands ²⁰⁴ Department of Medicine, University of Turku and Turku University Hospital, 20520 Turku, Finland ²⁰⁵ INSERM Cardiovascular Genetics team, CIC 9501, 54000 Nancy, France ²⁰⁶ Steno Diabetes Center, 2820 Gentofte, Denmark ²⁰⁷ Center for Human Genomics, Wake Forest University, Winston-Salem, North Carolina 27157, USA ²⁰⁸ Department of Psychiatrics, Lapland Central Hospital, 96101 Rovaniemi, Finland ²⁰⁹ School of Pathology and Laboratory Medicine, University of Western Australia, Nedlands, Western Australia 6009, Australia ²¹⁰ Department of Internal Medicine, University of Oulu, 90014 Oulu, Finland ²¹¹ School of Medicine and Pharmacology, University of Western Australia, Perth, Western Australia 6009, Australia ²¹² Department of Clinical Physiology, University of Tampere and Tampere University Hospital, 33520 Tampere, Finland; ²¹³ Stanford University School of Medicine, Stanford, California 93405, USA ²¹⁴ Department of Psychiatry and Human Behavior, University of California, Irvine (UCI), Irvine, California 92617, USA ²¹⁵ LIFE Study Centre, University of Leipzig, Leipzig, Germany ²¹⁶ Service of Medical Genetics, Centre Hospitalier Universitaire Vaudois (CHUV) University Hospital, 1011 Lausanne, Switzerland ²¹⁷ Human Genetics Center and Institute of Molecular Medicine, University of Texas Health Science Center, Houston, Texas 77030, USA ²¹⁸ Faculty of Health Science, University of Southern Denmark, 5000 Odense, Denmark ²¹⁹ New York University Medical Center, New York, New York 10016, USA ²²⁰ National Institute for Health and Welfare, Department of Mental Health and Substance Abuse Services, Unit for Child and Adolescent Mental Health, 00271 Helsinki, Finland ²²¹ NIHR Oxford Biomedical Research Centre, Churchill Hospital, Oxford, OX3 7LJ, UK ²²² Department of Urology, Radboud University Nijmegen Medical Centre, 6500 HB Nijmegen, The Netherlands ²²³ Institute of

Biomedical Sciences, University of Copenhagen, 2200 Copenhagen, Denmark ²²⁴ Faculty of Health Science, University of Aarhus, 8000 Aarhus, Denmark ²²⁵ Department of Psychiatry, Leiden University Medical Centre, 2300 RC Leiden, The Netherlands ²²⁶ Department of Psychiatry, University Medical Centre Groningen, 9713 GZ Groningen, The Netherlands ²²⁷ Department of Neurology, University of Lübeck, Lübeck, Germany ²²⁸ Institute for Paediatric Nutrition Medicine, Vestische Hospital for Children and Adolescents, University of Witten-Herdecke, 45711 Datteln, Germany ²²⁹ Department of Medicine III, Prevention and Care of Diabetes, University of Dresden, 01307 Dresden, Germany ²³⁰ Geriatrics Research and Education Clinical Center, Baltimore Veterans Administration Medical Center, Baltimore, Maryland 21201, USA ²³¹ Hjelt Institute, Department of Public Health, University of Helsinki, 00014 Helsinki, Finland ²³² South Ostrobothnia Central Hospital, 60220 Seinajoki, Finland ²³³ Department of Internal Medicine, Centre Hospitalier Universitaire Vaudois (CHUV) University Hospital, 1011 Lausanne, Switzerland ²³⁴ The Broad Institute of Harvard and MIT, Cambridge, Massachusetts 02142, USA ²³⁵ Department of Psychiatry, Harvard Medical School, Boston, Massachusetts 02115, USA ²³⁶ Pacific Biosciences, Menlo Park, California 94025, USA ²³⁷ Sage Bionetworks, Seattle, Washington 98109, USA ²³⁸ Division of Biostatistics, Washington University School of Medicine, St. Louis, Missouri 63110, USA ²³⁹ Division of Intramural Research, National Heart, Lung and Blood Institute, Framingham Heart Study, Framingham, Massachusetts 01702, USA ²⁴⁰ Department of Epidemiology and Population Health, Albert Einstein College of Medicine, Bronx, New York 10461, USA ²⁴¹ Department of Genetics, University of North Carolina, Chapel Hill, North Carolina 27599, USA ²⁴² Department of Medical Genetics, University of Helsinki, 00014 Helsinki, Finland ²⁴³ Laboratory of Genetics, National Institute on Aging, Baltimore, Maryland 21224, USA ²⁴⁴ Division of Community Health Sciences, St George's, University of London, London, SW17 0RE, UK ²⁴⁵ Klinikum Grosshadern, 81377 Munich, Germany ²⁴⁶ Faculty of Medicine, University of Iceland, 101 Reykjavík, Iceland ²⁴⁷ University of Cambridge Metabolic Research Labs, Institute of Metabolic Science Addenbrooke's Hospital, CB2 0QQ, Cambridge, UK ²⁴⁸ Carolina Center for Genome Sciences, School of Public Health, University of North Carolina Chapel Hill, Chapel Hill, North Carolina 27514, USA ²⁴⁹ Department of Genetics, Harvard Medical School, Boston, Massachusetts 02115, USA

Abstract

Obesity is globally prevalent and highly heritable, but the underlying genetic factors remain largely elusive. To identify genetic loci for obesity-susceptibility, we examined associations between body mass index (BMI) and ~2.8 million SNPs in up to 123,865 individuals, with targeted follow-up of 42 SNPs in up to 125,931 additional individuals. We confirmed 14 known obesity-susceptibility loci and identified 18 new loci associated with BMI ($P < 5 \times 10^{-8}$), one of which includes a copy number variant near *GPRC5B*. Some loci (*MC4R*, *POMC*, *SH2B1*, *BDNF*) map near key hypothalamic regulators of energy balance, and one is near *GIPR*, an incretin receptor. Furthermore, genes in other newly-associated loci may provide novel insights into human body weight regulation.

Obesity is a major and increasingly prevalent risk factor for multiple disorders, including type 2 diabetes and cardiovascular disease^{1,2}. While lifestyle changes have driven its prevalence to epidemic proportions, heritability studies provide evidence for a substantial genetic contribution ($h^2 \sim 40\text{--}70\%$) to obesity risk^{3,4}. BMI is an inexpensive, non-invasive measure of obesity that predicts the risk of related complications⁵. Identifying genetic determinants of BMI could lead to a better understanding of the biological basis of obesity.

Genome-wide association (GWA) studies of BMI have previously identified ten loci with genome-wide significant ($P < 5 \times 10^{-8}$) associations in or near *FTO*, *MC4R*, *TMEM18*,

GNPDA2, BDNF, NEGR1, SH2B1, ETV5, MTCH2, and KCTD15^{6–10}. Many of these genes are expressed or known to act in the central nervous system, highlighting a likely neuronal component to the predisposition to obesity⁹. This pattern is consistent with results in animal models and studies of monogenic human obesity, where neuronal genes, particularly those expressed in the hypothalamus and involved in regulation of appetite or energy balance, are known to play a major role in susceptibility to obesity^{11–13}.

The ten previously identified loci account for only a small fraction of the variation in BMI. Furthermore, power calculations based on the effect sizes of established variants have suggested that increasing the sample size would likely lead to the discovery of additional variants⁹. To identify more loci associated with BMI, we expanded the GIANT (Genetic Investigation of ANthropometric Traits) consortium GWA meta-analysis to include a total of 249,769 individuals of European ancestry.

Results

Stage 1 GWA studies identify novel loci associated with BMI

We first conducted a meta-analysis of GWA studies of BMI and ~2.8 million imputed or genotyped SNPs using data from 46 studies including up to 123,865 individuals (Online Methods, Supplementary Fig. 1 and Supplementary Note). This stage 1 analysis revealed 19 loci associated with BMI at $P < 5 \times 10^{-8}$ (Table 1, Fig. 1a and Supplementary Table 1). These 19 loci included all ten loci from previous GWA studies of BMI^{6–10}, two loci previously associated with body weight¹⁰ (*FAIM2* and *SEC16B*) and one locus previously associated with waist circumference¹⁴ (near *TFAP2B*). The remaining six loci, near *GPRC5B*, *MAP2K5/LBXCOR1*, *TNNI3K*, *LRRN6C*, *FLJ35779/HMGCR*, and *PRKD1*, have not previously been associated with BMI or other obesity-related traits.

Stage 2 follow-up leads to additional novel loci for BMI

To identify additional BMI-associated loci and to validate the loci that reached genome-wide significance in stage 1 analyses, we examined SNPs representing 42 independent loci (including the 19 genome-wide significant loci) with stage 1 $P < 5 \times 10^{-6}$. Variants were considered to be independent if the pair-wise linkage disequilibrium (LD; r^2) was less than 0.1 and if they were separated by at least 1 Mb. In stage 2, we examined these 42 SNPs in up to 125,931 additional individuals (79,561 newly genotyped individuals from 16 different studies and 46,370 individuals from 18 additional studies for which GWA data were available; Table 1, Supplementary Note, and Online Methods). In a joint analysis of stage 1 and stage 2 results, 32 of the 42 SNPs reached $P < 5 \times 10^{-8}$. Even after excluding SNPs within these 32 confirmed BMI loci, we still observed an excess of small P -values compared to the distribution expected under the null hypothesis (Fig. 1b), suggesting that more BMI loci remain to be uncovered.

The 32 confirmed associations included all 19 loci with $P < 5 \times 10^{-8}$ at stage 1, 12 additional novel loci near *RBJ/ADCY3/POMC*, *QPCTL/GIPR*, *SLC39A8*, *TMEM160*, *FANCL*, *CADM2*, *LRP1B*, *PTBP2*, *MTIF3/GTF3A*, *ZNF608*, *RPL27A/TUB*, *NUDT3/HMGAI*, and one locus (*NRXN3*) previously associated with waist circumference¹⁵ (Table 1, Supplementary Table 1, Supplementary Fig. 1 and 2). In all, our study increased the number of loci robustly associated with BMI from 10 to 32. Four of the 22 new loci were previously associated with body weight¹⁰ or waist circumference^{14,15}, whereas 18 loci had not previously associated with any obesity-related trait in the general population. Whilst we confirmed all loci previously established by large-scale GWA studies for BMI^{6–10} and waist circumference^{14,15}, four loci identified by GWA studies for early-onset or adult morbid obesity^{16,17} [at *NPC1* (rs1805081; $P = 0.0025$), *MAF* (rs1424233; $P = 0.25$), *PTER*

(rs10508503; $P = 0.64$), and *TNKS/MSRA* (rs473034; $P = 0.23$)] showed limited or no evidence of association with BMI in our study.

As expected, the effect sizes of the 18 newly discovered loci are slightly smaller, for a given minor allele frequency, than those of the previously identified variants (Table 1 and Fig. 1c). The increased sample size also brought out more signals with low minor allele frequency. The BMI-increasing allele frequencies for the 18 newly identified variants ranged from 4% to 87%, covering more of the allele frequency spectrum than previous, smaller GWA studies of BMI (24%–83%)^{9,10} (Table 1 and Fig. 1c).

We tested for evidence of non-additive (dominant or recessive) effects, SNP×SNP interaction effects and heterogeneity by sex or study among the 32 BMI-associated SNPs (Online Methods). We found no evidence for any such effects ($P > 0.001$, no significant results after correcting for multiple testing) (Supplementary Tables 1 and Supplementary Note).

Impact of 32 confirmed loci on BMI, obesity, body size, and other metabolic traits

Together, the 32 confirmed BMI loci explained 1.45% of the inter-individual variation in BMI of the stage 2 samples, with the *FTO* SNP accounting for the largest proportion of the variance (0.34%) (Table 1). To estimate the cumulative effect of the 32 variants on BMI, we constructed a genetic-susceptibility score that sums the number of BMI-increasing alleles weighted by the overall stage 2 effect sizes in the ARIC study ($N = 8,120$), one of our largest population-based studies (Online Methods). For each unit increase in the genetic-susceptibility score, approximately equivalent to one additional risk allele, BMI increased by 0.17 kg/m², equivalent to a 435–551 g gain in body weight in adults of 160–180 cm in height. The difference in average BMI between individuals with a high genetic-susceptibility score (38 BMI-increasing alleles, 1.5% ($n=124$) of the ARIC sample) and those with a low genetic-susceptibility score (21 BMI-increasing alleles, 2.2% ($n=175$) of the ARIC sample) was 2.73 kg/m², equivalent to a 6.99 to 8.85 kg body weight difference in adults 160–180 cm in height (Fig. 2a). Still, we note that the predictive value for obesity risk and BMI of the 32 variants combined was modest, although statistically significant (Fig. 2b, Supplementary Fig. 4). The area under the receiver operating characteristic (ROC) curve for prediction of risk of obesity (BMI ≥ 30 kg/m²) using age, age² and sex only was 0.515 ($P = 0.023$ compared to AUC of 0.50), which increased to 0.575 ($P < 10^{-5}$) when also the 32 confirmed SNPs were included in the model (Fig. 2b). The area under the ROC for the 32 SNPs only was 0.574 ($P < 10^{-5}$).

All 32 confirmed BMI-increasing alleles showed directionally consistent effects on risk of being overweight (BMI ≥ 25 kg/m²) or obese (≥ 30 kg/m²) in stage 2 samples, with 30 of 32 variants achieving at least nominally significant associations. The BMI-increasing alleles increased the odds of overweight by 1.013 to 1.138-fold, and the odds for being obese by 1.016- to 1.203-fold (Supplementary Table 2). In addition, 30 of the 32 loci also showed directionally consistent effects on the risk of extreme and early-onset obesity in a meta-analysis of seven case-control studies of adults and children (binomial sign test $P = 1.3 \times 10^{-7}$) (Supplementary Table 3). The BMI-increasing allele observed in adults also increased the BMI in children and adolescents with directionally consistent effects observed for 23 of the 32 SNPs (binomial sign test $P = 0.01$). Furthermore, in family-based studies, the BMI-increasing allele was over-transmitted to the obese offspring for 24 of the 32 SNPs (binomial sign test $P = 0.004$) (Supplementary Table 3). As these studies in extreme obesity cases, children and families were relatively small ($N_{\text{range}} = 354 - 15,251$) compared to the overall meta-analyses, their power was likely insufficient to confirm association for all 32 loci. Nevertheless, these results show that the effects are unlikely to reflect population stratification and that they extend to BMI differences throughout the life course.

All BMI-increasing alleles were associated with increased body weight, as expected from the correlation between BMI and body weight (Supplementary Table 2). To confirm an effect of the loci on adiposity rather than general body size, we tested association with body fat percentage, which was available in a subset of the stage 2 replication samples ($n = 5,359-28,425$) (Supplementary Table 2). The BMI-increasing allele showed directionally consistent effects on body fat percentage at 31 of the 32 confirmed loci (binomial sign test $P = 1.54 \times 10^{-8}$) (Supplementary Table 2).

We also examined the association of the BMI loci with metabolic traits (type 2 diabetes¹⁸, fasting glucose, fasting insulin, indices of beta-cell function (HOMA-B) and insulin resistance (HOMA-IR)¹⁹, and blood lipid levels²⁰) and with height (Supplementary Tables 2 and 4). Although many nominal associations are expected because of known correlations between BMI and most of these traits and because of overlap in samples, several associations stand out as possible examples of pleiotropic effects of the BMI-associated variants. Particularly interesting is the variant in the *GIPR* locus where the BMI-increasing allele is also associated with increased fasting glucose levels and lower 2-hour glucose levels (Supplementary Table 4)^{19,21}. The direction of the effect is opposite to what would be expected due to the correlation between obesity and glucose intolerance, but is consistent with the suggested roles of *GIPR* in glucose and energy metabolism (see below)²². Three loci show strong associations ($P < 10^{-4}$) with height (*MC4R*, *RBJ/ADCY3/POMC* and *MTCH2/NDUFS3*). Because BMI is weakly correlated with height (and indeed, the BMI-associated variants as a group show no consistent effect on height), these associations are also suggestive of pleiotropy. Interestingly, analogous to the effects of severe mutations in *POMC* and *MC4R* on height and weight^{23,24}, the BMI-increasing alleles of the variants near these genes were associated with decreased (*POMC*) and increased (*MC4R*) height, respectively (Supplementary Table 2).

Potential functional roles and pathways analyses

Although associated variants typically implicate genomic regions rather than individual genes, we note that some of the 32 loci include candidate genes with established connections to obesity. Several of the 10 previously identified loci are located in or near genes that encode neuronal regulators of appetite or energy balance, including *MC4R*^{12,25}, *BDNF*²⁶, and *SH2B1*^{11,27}. Each of these genes has been tied to obesity, not only in animal models, but also by rare human variants that disrupt each of these genes and lead to severe obesity^{24,28,29}. Using the automated literature search programme, Snipper (Online Methods), we identified various genes within the novel loci with potential biological links to obesity-susceptibility (Supplementary Note). Among the novel loci, the location of rs713586 near *POMC* provides further support for a role of neuroendocrine circuits that regulate energy balance in susceptibility to obesity. *POMC* encodes several polypeptides including α -MSH, a ligand of the *MC4R* gene product³⁰, and rare mutations in *POMC* also cause human obesity^{23,29,31}.

In contrast, the locus near *GIPR*, which encodes a receptor of gastric inhibitory polypeptide (GIP), suggests a role for peripheral biology in obesity. GIP, which is expressed in the K cell of the duodenum and intestine, is an incretin hormone that mediates incremental insulin secretion in response to oral intake of glucose. The variant associated with BMI is in strong LD ($r^2 = 0.83$) with a missense SNP in *GIPR* (rs1800437, Glu354Gln) that has recently been shown to influence the glucose and insulin response to an oral glucose challenge²¹. Although no human phenotype is known to be caused by mutations in *GIPR*, mice with disruption of *Gipr* are resistant to diet-induced obesity³². The association of a variant in *GIPR* with BMI suggests that there may be a link between incretins/insulin secretion and body weight regulation in humans as well.

To systematically identify biological connections among the genes located near the 32 confirmed SNPs, and to potentially identify new pathways associated with BMI, we performed pathway-based analyses using MAGENTA³³. Specifically, we tested for enrichment of BMI genetic associations in biological processes or molecular functions that contain at least one gene from the 32 confirmed BMI loci (Online Methods). Using annotations from the KEGG, Ingenuity, PANTHER, and Gene Ontology databases, we found evidence of enrichment for pathways involved in the platelet-derived growth factor (PDGF) signaling (PANTHER, $P = 0.0008$, $FDR = 0.0061$), translation elongation (PANTHER, $P = 0.0008$, $FDR = 0.0066$), hormone or nuclear hormone receptor binding (Gene Ontology, $P < 0.0005$, $FDR < 0.0085$), homeobox transcription (PANTHER, $P = 0.0001$, $FDR = 0.011$), regulation of cellular metabolism (Gene Ontology, $P = 0.0002$, $FDR = 0.031$), neurogenesis and neuron differentiation (Gene Ontology, $P < 0.0002$, $FDR < 0.034$), protein phosphorylation (PANTHER, $P = 0.0001$, $FDR = 0.045$) and numerous other pathways related to growth, metabolism, immune and neuronal processes (Gene Ontology, $P < 0.002$, $FDR < 0.046$) (Supplementary Table 5).

Identifying possible functional variants

We used data from the 1000 Genomes Project and the HapMap Consortium to explore whether the 32 confirmed BMI SNPs were in LD ($r^2 \geq 0.75$) with common missense SNPs or copy number variants (CNVs) (Online Methods). Non-synonymous variants in LD with our signals were present in the *BDNF*, *SLC39A8*, *FLJ35779/HMGCR*, *QPCTL/GIPR*, *MTCH2*, *ADCY3*, and *LBXCOR1* genes. In addition, the rs7359397 signal was in LD with coding variants in several genes including *SH2B1*, *ATNX2L*, *APOB48R*, *SULT1A2*, and *AC138894.2* (Table 1, Fig. 3, Supplementary Table 6 and Supplementary Fig. 2). Furthermore, two SNPs tagged common CNVs. The first CNV was previously identified and is a 45-kb deletion near *NEGR1*⁹. The second CNV is a 21-kb deletion that lies 50kb upstream of *GPRC5B*; the deletion allele is tagged by the T-allele of rs12444979 ($r^2 = 1$) (Fig. 3). Although the correlations with potentially functional variants does not prove that these variants are indeed causal, these provide first clues as to which genes and variants at these loci might be prioritized for fine-mapping and functional follow-up.

As many of the 32 BMI loci harbor multiple genes, we examined whether gene expression (eQTL) analyses could also direct us to positional candidates. Gene expression data were available for human brain, lymphocytes, blood, subcutaneous and visceral adipose tissue, and liver^{34–36} (Online Methods, Table 1 and Supplementary Table 7). Significant *cis*-associations, defined at the tissue-specific level, were observed between 14 BMI-associated alleles and expression levels (Table 1 and Supplementary Table 7). In several cases, the BMI-associated SNP was the most significant SNP or explained a substantial proportion of the association with the most significant SNP for the gene transcript in conditional analyses ($P_{adj} > 0.05$). These significant associations included *NEGR1*, *ZC3H4*, *TMEM160*, *MTCH2*, *NDUFS3*, *GTF3A*, *ADCY3*, *APOB48R*, *SH2B1*, *TUFM*, *GPRC5B*, *IQCK*, *SLC39A8*, *SULT1A1*, and *SULT1A2* (Table 1 and Supplementary Table 7), making these genes higher priority candidates within the associated loci. However, we note that some BMI-associated variants were correlated with the expression of multiple nearby genes, making it difficult to determine the most relevant gene.

Evidence for the existence of additional associated variants

Because the variants identified by this large study explain only 1.45% of the variance in BMI (2–4% of genetic variance based on an estimated heritability of 40–70%), we considered how much the explained phenotypic variance could be increased by including more SNPs at various degrees of significance in a polygene model using an independent validation set (Online Methods)³⁷. We found that including SNPs associated with BMI at

lower significance levels (up to $P > 0.05$) increased the explained phenotypic variance in BMI to 2.5%, or 4% to 6% of genetic variance (Fig. 4a). In a separate analysis, we estimated the total number of independent BMI-associated variants that are likely to exist with similar effect sizes to the 32 confirmed here (Online Methods)³⁸. Based on the effect size and allele frequencies of the 32 replicated loci observed in stage 2 and the power to detect association in the combined stage 1 and stage 2, we estimated that there are 284 (95% CI: 132–510) loci with similar effect sizes as the currently observed ones, which together would account for 4.5% (95% CI: 3.1–6.8%) of the variation in BMI or 6–11% of the genetic variation (based on an estimated heritability of 40–70%) (Supplementary Table 8). In order to detect 95% of these loci, a sample size of approximately 730,000 subjects would be needed (Fig. 4b). This method does not account for the potential of loci of smaller effect than those identified here to explain even more of the variance and thus provides an estimated lower bound of explained variance. These two analyses strongly suggest that larger GWA studies will continue to identify additional novel associated loci, but also indicate that even extremely large studies focusing on variants with allele frequencies above 5% will not account for a large fraction of the genetic contribution to BMI.

We examined whether selecting only a single variant from each locus for follow-up led us to underestimate the fraction of phenotypic variation explained by the associated loci. To search for additional independent loci at each of the 32 associated BMI loci, we repeated our GWA meta-analysis, conditioning on the 32 confirmed SNPs. Using a significance threshold of 5×10^{-6} for SNPs at known loci, we identified one apparently independent signal at the *MC4R* locus; rs7227255 was associated with BMI ($P = 6.56 \times 10^{-7}$) even after conditioning for the most strongly associated variant near *MC4R* (rs571312) (Fig. 5). Interestingly, rs7227255 is in perfect LD ($r^2 = 1$) with a relatively rare *MC4R* missense variant (rs2229616, V103I, minor allele frequency = 1.7%) that has been associated with BMI in two independent meta-analyses^{39,40}. Furthermore, mutations at the *MC4R* locus are known to influence early-onset obesity^{24,41}, supporting the notion that allelic heterogeneity may be a frequent phenomenon in the genetic architecture of obesity.

Discussion

Using a two-stage genome-wide association meta-analysis of up to 249,796 individuals of European descent, we have identified 18 additional loci that are associated with BMI at genome-wide significance, bringing the total number of such loci to 32. We estimate that more than 250 (i.e. 284 predicted loci – 32 confirmed loci) common variant loci with effects on BMI similar to those described here remain to be discovered, and even larger numbers of loci with smaller effects. A substantial proportion of these loci should be identifiable through larger GWA studies and/or by targeted follow-up of top signals selected from our stage 1 analysis. The latter approach is already being implemented through large-scale genotyping of samples informative for BMI using a custom array (the Metabochip) designed to support follow-up of thousands of promising variants in hundreds of thousands of individuals.

The combined effect on BMI of the associated variants at the 32 loci is modest, and even when we try to account for as-yet-undiscovered variants with similar properties, we estimate that these common variant signals account for only 6–11% of the genetic variation in BMI. There is a strong expectation that additional variance and biology will be explained using complementary approaches that capture variants not examined in the current study, such as lower frequency variants and short insertion-deletion polymorphisms. There is good reason to believe (based on our findings at *MC4R* and other loci – *POMC*, *BDNF*, *SH2B1* – which feature both common and rare variant associations) that a proportion of such low-frequency and rare causal variation will map to the loci already identified by GWA studies.

A primary goal of human genetic discovery is to improve understanding of the biology of conditions such as obesity⁴². One particularly interesting finding in this regard is the association between BMI and common variants near *GIPR*, which may indicate a causal contribution of variation in postprandial insulin secretion to the development of obesity. In most cases, the loci identified by the present study harbor few, if any, annotated genes with clear connections to the biology of weight regulation. This reflects our still limited understanding of the biology of BMI and obesity-related traits and is in striking contrast with the results from equivalent studies of certain other traits (such as autoimmune diseases or lipid levels). Thus, these results suggest that much novel biology remains to be uncovered, and that GWA studies may provide an important entry point. In particular, further examination of the associated loci through a combination of resequencing and fine-mapping to find causal variants, and genomic and experimental studies designed to assign function, could uncover novel insights into the biology of obesity.

In conclusion, we have performed GWA studies in large samples to identify numerous genetic loci associated with variation in BMI, a common measure of obesity. Because current lifestyle interventions are largely ineffective in addressing the challenges of growing obesity^{43,44}, new insights into biology are critically needed to guide the development and application of future therapies and interventions.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

A full list of acknowledgments appears in the Supplementary Note.

Academy of Finland (10404, 77299, 104781, 114382, 117797, 120315, 121584, 124243, 126775, 126925, 127437, 129255, 129269, 129306, 129494, 129680, 130326, 209072, 210595, 213225, 213506, 216374); ADA Mentor-Based Postdoctoral Fellowship; Amgen; Agency for Science, Technology and Research of Singapore (A*STAR); ALF/LUA research grant in Gothenburg; Althingi (the Icelandic Parliament); AstraZeneca; Augustinus Foundation; Australian National Health and Medical Research Council (241944, 389875, 389891, 389892, 389938, 442915, 442981, 496739, 496688, 552485 and 613672); Australian Research Council (ARC grant DP0770096); Becket Foundation; Biocenter (Finland); Biomedicum Helsinki Foundation, Boston Obesity Nutrition Research Center; British Diabetes Association (1192); British Heart Foundation (97020; PG/02/128); Busselton Population Medical Research Foundation; Cambridge Institute for Medical Research; Cambridge NIHR Comprehensive Biomedical Research Centre; CamStrad (UK); Cancer Research UK; Centre for Medical Systems Biology (The Netherlands); Centre for Neurogenomics and Cognitive Research (The Netherlands); Chief Scientist Office of the Scottish Government; Contrat Plan Etat Région (France); Danish Centre for Health Technology Assessment; Danish Diabetes Association; Danish Heart Foundation; Danish Pharmaceutical Association; Danish Research Council; Deutsche Forschungsgemeinschaft (DFG; HE 1446/4-1); Department of Health (UK); Diabetes UK; Diabetes & Inflammation Laboratory; Donald W. Reynolds Foundation; Dresden University of Technology Funding Grant; Emil and Vera Cornell Foundation; Erasmus Medical Center (Rotterdam); Erasmus University (Rotterdam); European Commission (DG XII; QLG1-CT-2000-01643, QLG2-CT-2002-01254, LSHC-CT-2005, LSHG-CT-2006-018947, LSHG-CT-2004-518153, LSH-2006-037593, LSHM-CT-2007-037273, HEALTH-F2-2008-ENGAGE, HEALTH-F4-2007-201413, HEALTH-F4-2007-201550, FP7/2007-2013, 205419, 212111, 245536, SOC 95201408 05F02, WLRT-2001-01254); Federal Ministry of Education and Research (Germany) (01AK803, 01EA9401, 01GI0823, 01GI0826, 01GP0209, 01GP0259, 01GS0820, 01GS0823, 01GS0824, 01GS0825, 01GS0830, 01GS0831, 01IG07015, 01KU0903, 01ZZ9603, 01ZZ0103, 01ZZ0403, 03ZIK012); Federal State of Mecklenburg-West Pomerania; European Social Fund; Eve Appeal; Finnish Diabetes Research Foundation; Finnish Foundation for Cardiovascular Research; Finnish Foundation for Pediatric Research, Finnish Medical Society; Finska Läkaresällskapet, Päivikki and Sakari Sohlberg Foundation, Folkhalsan Research Foundation; Fond Européen pour le Développement Régional (France); Fondation LeDucq (Paris, France); Foundation for Life and Health in Finland; Foundation for Strategic Research (Sweden); Genetic Association Information Network; German Research Council (KFO-152) German National Genome Research Net 'NGFNplus' (FKZ 01GS0823); German Research Center for Environmental Health; Giorgi-Cavaglieri Foundation; GlaxoSmithKline; Göteborg Medical Society; Great Wine Estates Auctions; Gyllenberg Foundation; Health Care Centers in Vasa, Närpes and Korsholm; Healthway, Western Australia; Helmholtz Center Munich; Helsinki University Central Hospital, Hjartavernd (the Icelandic Heart Association); INSERM (France); Ib Henriksen Foundation; IZKF (B27); Jalmari and Rauha

Ahokas Foundation; Juho Vainio Foundation; Juvenile Diabetes Research Foundation International (JDRF); Karolinska Institute; Knut and Alice Wallenberg Foundation; Leenaards Foundation; Lundbeck Foundation Centre of Applied Medical Genomics for Personalized Disease Prediction, Prevention and Care (LUCAMP); Lundberg Foundation; Marie Curie Intra-European Fellowship; Medical Research Council (UK) (G0000649, G0000934, G9521010D, G0500539, G0600331, G0601261, PrevMetSyn); Ministry of Cultural Affairs and Social Ministry of the Federal State of Mecklenburg-West Pomerania; Ministry for Health, Welfare and Sports (Netherlands); Ministry of Education (Finland); Ministry of Education, Culture and Science (Netherlands); Ministry of Internal Affairs and Health (Denmark); Ministry of Science, Education and Sport of the Republic of Croatia (216-1080315-0302); Ministry of Science, Research and the Arts Baden-Württemberg; Montreal Heart Institute Foundation; Municipal Health Care Center and Hospital in Jakobstad; Municipality of Rotterdam; Närpes Health Care Foundation; National Cancer Institute; National Health and Medical Research Council of Australia; National Institute for Health Research Cambridge Biomedical Research Centre; National Institute for Health Research Oxford Biomedical Research Centre; National Institute for Health Research comprehensive Biomedical Research Centre; National Institutes of Health (263-MA-410953, AA07535, AA10248, AA014041, AA13320, AA13321, AA13326, CA047988, CA65725, CA87969, CA49449, CA67262, CA50385, DA12854, DK58845, DK46200, DK062370, DK063491, DK072193, HG002651, HL084729, HHSN268200625226C, HL71981, K23-DK080145, K99-HL094535, M01-RR00425, MH084698, N01-AG12100, N01-AG12109, N01-HC15103, N01-HC25195, N01-HC35129, N01-HC45133, N01-HC55015, N01-HC55016, N01-HC55018, N01-HC55019, N01-HC55020, N01-N01HC-55021, N01-HC55022, N01-HC55222, N01-HC75150, N01-HC85079, N01-HC85080, N01-HG-65403, N01-HC85081, N01-HC85082; N01-HC85083; N01-HC85084; N01-HC85085; N01-HC85086, N02-HL64278, P30-DK072488, R01-AG031890, R01-DK073490, R01-DK075787, R01DK068336, R01DK075681, R01-HL59367, R01-HL086694, R01-HL087641, R01-HL087647, R01-HL087652, R01-HL087676, R01-HL087679, R01-HL087700, R01-HL088119, R01-MH59160, R01-MH59565, R01-MH59566, R01-MH59571, R01-MH59586, R01-MH59587, R01-MH59588, R01-MH60870, R01-MH60879, R01-MH61675, R01-MH63706, R01-MH67257, R01-MH79469, R01-MH79470, R01-MH81800, RL1-MH083268, U01-CA098233, U01-DK062418, U01-GM074518, U01-HG004402, U01-HG004399, U01-HL72515, U01-HL080295, U01-HL084756, U54-RR020278, T32-HG00040, UL1-RR025005, Z01-HG000024); National Alliance for Research on Schizophrenia and Depression (NARSAD); Netherlands Genomics Initiative/Netherlands Consortium for Healthy Aging (050-060-810); Netherlands Organisation for Scientific Research (NWO) (904-61-090, 904-61-193, 480-04-004, 400-05-717, SPI 56-464-1419, 175.010.2005.011, 911-03-012); Nord-Trøndelag County Council; Nordic Center of Excellence in Disease Genetics; Novo Nordisk Foundation; Norwegian Institute of Public Health; Ollqvist Foundation; Oxford NIHR Biomedical Research Centre; Organization for the Health Research and Development (10-000-1002); Paavo Nurmi Foundation; Paul Michael Donovan Charitable Foundation; Perklén Foundation; Petrus and Augusta Hedlunds Foundation; Pew Scholar for the Biomedical Sciences; Public Health and Risk Assessment, Health & Consumer Protection (2004310); Research Foundation of Copenhagen County; Research Institute for Diseases in the Elderly (014-93-015; RIDE2); Robert Dawson Evans Endowment; Royal Society (UK); Royal Swedish Academy of Science; Sahlgrenska Center for Cardiovascular and Metabolic Research (CMR, no. A305: 188); Siemens Healthcare, Erlangen, Germany; Sigrid Juselius Foundation; Signe and Ane Gyllenberg Foundation; Science Funding programme (UK); Social Insurance Institution of Finland; Söderberg's Foundation; South Tyrol Ministry of Health; South Tyrolean Sparkasse Foundation; State of Bavaria; Stockholm County Council (560183); Susan G. Komen Breast Cancer Foundation; Swedish Cancer Society; Swedish Cultural Foundation in Finland; Swedish Foundation for Strategic Research; Swedish Heart-Lung Foundation; Swedish Medical Research Council (8691, K2007-66X-20270-01-3, K2010-54X-09894-19-3, K2010-54X-09894-19-3, 2006-3832); Swedish Research Council; Swedish Society of Medicine; Swiss National Science Foundation (33CSO-122661, 310000-112552, 3100AO-116323/1); Torsten and Ragnar Söderberg's Foundation; Université Henri Poincaré-Nancy 1, Région Lorraine, Communauté Urbaine du Grand Nancy; University Hospital Medical funds to Tampere; University Hospital Oulu; University of Oulu, Finland (75617); Västra Götaland Foundation; Walter E. Nichols, M.D., and Eleanor Nichols endowments; Wellcome Trust (068545, 072960, 075491, 076113, 077016, 079557, 079895, 081682, 083270, 085301, 086596); Western Australian DNA Bank; Western Australian Genetic Epidemiology Resource; Yrjö Jahnsson Foundation.

References

1. Clinical Guidelines on the Identification, Evaluation, and Treatment of Overweight and Obesity in Adults--The Evidence Report. National Institutes of Health. *Obes Res.* 1998; 6 (Suppl 2):51S–209S. [PubMed: 9813653]
2. Lewis CE, et al. Mortality, health outcomes, and body mass index in the overweight range: a science advisory from the American Heart Association. *Circulation.* 2009; 119:3263–71. [PubMed: 19506107]
3. Stunkard AJ, Foch TT, Hrubec Z. A twin study of human obesity. *Jama.* 1986; 256:51–4. [PubMed: 3712713]
4. Maes HH, Neale MC, Eaves LJ. Genetic and environmental factors in relative body weight and human adiposity. *Behav Genet.* 1997; 27:325–51. [PubMed: 9519560]

5. Taylor AE, et al. Comparison of the associations of body mass index and measures of central adiposity and fat mass with coronary heart disease, diabetes, and all-cause mortality: a study using data from 4 UK cohorts. *Am J Clin Nutr.* 2010; 91:547–56. [PubMed: 20089729]
6. Frayling TM, et al. A common variant in the FTO gene is associated with body mass index and predisposes to childhood and adult obesity. *Science.* 2007; 316:889–94. [PubMed: 17434869]
7. Scuteri A, et al. Genome-wide association scan shows genetic variants in the FTO gene are associated with obesity-related traits. *PLoS Genet.* 2007; 3:e115. [PubMed: 17658951]
8. Loos RJ, et al. Common variants near MC4R are associated with fat mass, weight and risk of obesity. *Nat Genet.* 2008; 40:768–75. [PubMed: 18454148]
9. Willer CJ, et al. Six new loci associated with body mass index highlight a neuronal influence on body weight regulation. *Nat Genet.* 2009; 41:25–34. [PubMed: 19079261]
10. Thorleifsson G, et al. Genome-wide association yields new sequence variants at seven loci that associate with measures of obesity. *Nat Genet.* 2009; 41:18–24. [PubMed: 19079260]
11. Ren D, et al. Neuronal SH2B1 is essential for controlling energy and glucose homeostasis. *J Clin Invest.* 2007; 117:397–406. [PubMed: 17235396]
12. Huszar D, et al. Targeted disruption of the melanocortin-4 receptor results in obesity in mice. *Cell.* 1997; 88:131–41. [PubMed: 9019399]
13. O’Rahilly S, Farooqi IS. Human obesity as a heritable disorder of the central control of energy balance. *Int J Obes (Lond).* 2008; 32 (Suppl 7):S55–61.
14. Lindgren CM, et al. Genome-wide association scan meta-analysis identifies three Loci influencing adiposity and fat distribution. *PLoS Genet.* 2009; 5:e1000508. [PubMed: 19557161]
15. Heard-Costa NL, et al. NRXN3 is a novel locus for waist circumference: a genome-wide association study from the CHARGE Consortium. *PLoS Genet.* 2009; 5:e1000539. [PubMed: 19557197]
16. Meyre D, et al. Genome-wide association study for early-onset and morbid adult obesity identifies three new risk loci in European populations. *Nat Genet.* 2009; 41:157–9. [PubMed: 19151714]
17. Scherag A, et al. Two new Loci for body-weight regulation identified in a joint analysis of genome-wide association studies for early-onset extreme obesity in French and German study groups. *PLoS Genet.* 2010; 6:e1000916. [PubMed: 20421936]
18. Zeggini E, et al. Meta-analysis of genome-wide association data and large-scale replication identifies additional susceptibility loci for type 2 diabetes. *Nat Genet.* 2008; 40:638–45. [PubMed: 18372903]
19. Dupuis J, et al. New genetic loci implicated in fasting glucose homeostasis and their impact on type 2 diabetes risk. *Nat Genet.* 2010; 42:105–16. [PubMed: 20081858]
20. Kathiresan S, et al. Common variants at 30 loci contribute to polygenic dyslipidemia. *Nat Genet.* 2009; 41:56–65. [PubMed: 19060906]
21. Saxena R, et al. Genetic variation in GIPR influences the glucose and insulin responses to an oral glucose challenge. *Nat Genet.* 2010; 42:142–8. [PubMed: 20081857]
22. McIntosh CH, Widenmaier S, Kim SJ. Glucose-dependent insulinotropic polypeptide (Gastric Inhibitory Polypeptide; GIP). *Vitam Horm.* 2009; 80:409–71. [PubMed: 19251046]
23. Farooqi IS, et al. Heterozygosity for a POMC-null mutation and increased obesity risk in humans. *Diabetes.* 2006; 55:2549–53. [PubMed: 16936203]
24. Farooqi IS, et al. Clinical spectrum of obesity and mutations in the melanocortin 4 receptor gene. *N Engl J Med.* 2003; 348:1085–95. [PubMed: 12646665]
25. Marsh DJ, et al. Response of melanocortin-4 receptor-deficient mice to anorectic and orexigenic peptides. *Nat Genet.* 1999; 21:119–22. [PubMed: 9916804]
26. Unger TJ, Calderon GA, Bradley LC, Sena-Esteves M, Rios M. Selective deletion of Bdnf in the ventromedial and dorsomedial hypothalamus of adult mice results in hyperphagic behavior and obesity. *J Neurosci.* 2007; 27:14265–74. [PubMed: 18160634]
27. Li Z, Zhou Y, Carter-Su C, Myers MG Jr, Rui L. SH2B1 enhances leptin signaling by both Janus kinase 2 Tyr813 phosphorylation-dependent and -independent mechanisms. *Mol Endocrinol.* 2007; 21:2270–81. [PubMed: 17565041]

28. Gray J, et al. Hyperphagia, severe obesity, impaired cognitive function, and hyperactivity associated with functional loss of one copy of the brain-derived neurotrophic factor (BDNF) gene. *Diabetes*. 2006; 55:3366–71. [PubMed: 17130481]
29. Bochukova EG, et al. Large, rare chromosomal deletions associated with severe early-onset obesity. *Nature*. 2010; 463:666–70. [PubMed: 19966786]
30. Coll AP, Loraine Tung YC. Pro-opiomelanocortin (POMC)-derived peptides and the regulation of energy homeostasis. *Mol Cell Endocrinol*. 2009; 300:147–51. [PubMed: 18840502]
31. Krude H, et al. Obesity due to proopiomelanocortin deficiency: three new cases and treatment trials with thyroid hormone and ACTH4–10. *J Clin Endocrinol Metab*. 2003; 88:4633–40. [PubMed: 14557433]
32. Miyawaki K, et al. Inhibition of gastric inhibitory polypeptide signaling prevents obesity. *Nat Med*. 2002; 8:738–42. [PubMed: 12068290]
33. Segrè AV, et al. Common Inherited Variation in Mitochondrial Genes is not Enriched for Associations with Type 2 Diabetes or Related Glycemic Traits. *PLoS Genetics*. 2010 in press.
34. Emilsson V, et al. Genetics of gene expression and its effect on disease. *Nature*. 2008; 452:423–8. [PubMed: 18344981]
35. Myers AJ, et al. A survey of genetic human cortical gene expression. *Nat Genet*. 2007; 39:1494–9. [PubMed: 17982457]
36. Dixon AL, et al. A genome-wide association study of global gene expression. *Nat Genet*. 2007; 39:1202–7. [PubMed: 17873877]
37. Purcell SM, et al. Common polygenic variation contributes to risk of schizophrenia and bipolar disorder. *Nature*. 2009; 460:748–52. [PubMed: 19571811]
38. Park J-H, et al. Estimation of effect size distribution from genome-wide association studies and implications for future discoveries. *Nat Genet*. 2010 accepted.
39. Young EH, et al. The V103I polymorphism of the MC4R gene and obesity: population based studies and meta-analysis of 29 563 individuals. *Int J Obes (Lond)*. 2007; 31:1437–41. [PubMed: 17356525]
40. Stutzmann F, et al. Non-synonymous polymorphisms in melanocortin-4 receptor protect against obesity: the two facets of a Janus obesity gene. *Hum Mol Genet*. 2007; 16:1837–44. [PubMed: 17519222]
41. Yeo GS, et al. Mutations in the human melanocortin-4 receptor gene associated with severe familial obesity disrupts receptor function through multiple molecular mechanisms. *Hum Mol Genet*. 2003; 12:561–74. [PubMed: 12588803]
42. Hirschhorn JN. Genomewide association studies--illuminating biologic pathways. *N Engl J Med*. 2009; 360:1699–701. [PubMed: 19369661]
43. Lemmens VE, Oenema A, Klepp KI, Henriksen HB, Brug J. A systematic review of the evidence regarding efficacy of obesity prevention interventions among adults. *Obes Rev*. 2008; 9:446–55. [PubMed: 18298429]
44. Anderson JW, Konz EC, Frederich RC, Wood CL. Long-term weight-loss maintenance: a meta-analysis of US studies. *Am J Clin Nutr*. 2001; 74:579–84. [PubMed: 11684524]
45. Li Y, Willer C, Sanna S, Abecasis G. Genotype imputation. *Annu Rev Genomics Hum Genet*. 2009; 10:387–406. [PubMed: 19715440]
46. Marchini J, Howie B, Myers S, McVean G, Donnelly P. A new multipoint method for genome-wide association studies by imputation of genotypes. *Nat Genet*. 2007; 39:906–13. [PubMed: 17572673]
47. Guan Y, Stephens M. Practical issues in imputation-based association mapping. *PLoS Genet*. 2008; 4:e1000279. [PubMed: 19057666]
48. Abecasis GR, Wigginton JE. Handling marker-marker linkage disequilibrium: pedigree analysis with clustered markers. *Am J Hum Genet*. 2005; 77:754–67. [PubMed: 16252236]
49. Aulchenko YS, Struchalin MV, van Duijn CM. ProbABEL package for genome-wide association analysis of imputed data. *BMC Bioinformatics*. 11:134. [PubMed: 20233392]
50. Aulchenko YS, Ripke S, Isaacs A, van Duijn CM. GenABEL: an R library for genome-wide association analysis. *Bioinformatics*. 2007; 23:1294–6. [PubMed: 17384015]

51. Purcell S, et al. PLINK: a tool set for whole-genome association and population-based linkage analyses. *Am J Hum Genet.* 2007; 81:559–75. [PubMed: 17701901]
52. Zhong H, Yang X, Kaplan LM, Molony C, Schadt EE. Integrating pathway analysis and genetics of gene expression for genome-wide association studies. *Am J Hum Genet.* 2010; 86:581–91. [PubMed: 20346437]




Figure 1. Genome-wide association results for the BMI meta-analysis
(a) Manhattan plot showing the significance of association between all SNPs and BMI in the stage 1 meta-analysis, highlighting SNPs previously reported to show genome-wide significant association with BMI (blue), weight or waist circumference (green), and the 18 new regions described here (red). The 19 SNPs that reached genome-wide significance at Stage 1 (13 previously reported and 6 new) are listed in Table 1. **(b)** Quantile-quantile (Q-Q) plot of SNPs in stage 1 meta-analysis (black) and after removing any SNPs within 1 Mb of the 10 previously reported genome-wide significant hits for BMI (blue), after additionally excluding SNPs from the four loci for waist/weight (green) and after excluding SNPs from all 32 confirmed loci (red). The plot was abridged at the Y-axis (at $P < 10^{-20}$) to better visualise the excess of small P -values after excluding the 32 confirmed loci (Supplementary Fig. 3 shows full-scale Q-Q plot). The shaded region is the 95% concentration band. **(c)** Plot of effect size (in inverse normally transformed units (invBMI)) versus effect allele frequency of newly identified and previously identified BMI variants after stage 1 + stage 2 analysis; including the 10 previously identified BMI loci (blue), the four previously identified waist and weight loci (green) and the 18 newly identified BMI loci (blue). The dotted lines represent the minimum effect sizes that could be identified for a given effect-allele frequency with 80% (upper line), 50% (middle line), and 10% (lower line) power, assuming a sample size of 123,000 individuals and a α -level of 5×10^{-8} .




Figure 2. Combined impact of risk alleles on BMI/obesity

(a) Combined effect of risk alleles on average BMI in the population-based Atherosclerosis Risk in Communities (ARIC) study ($n = 8,120$ individuals of European descent). For each individual, the number of “best guess” replicated ($n = 32$) risk alleles from imputed data (0,1,2) per SNP was weighted for their relative effect sizes estimated from the stage 2 data. Weighted risk alleles were summed for each individual and the overall individual sum was rounded to the nearest integer to represent the individual’s risk allele score (range 16–44). Along the x-axis, individuals in each risk allele category are shown (grouped ≤ 21 and ≥ 38 at the extremes), and the mean BMI (\pm SEM) is plotted (y axis on right), with the line representing the regression of the mean BMI values across the risk-allele scores. The histogram (y-axis on left) represents the number of individuals in each risk-score category.

(b) The area under the ROC curve (AUC) of two different models predicting the risk of obesity ($\text{BMI} = 30 \text{ kg/m}^2$) in the $n = 8,120$ genotyped individuals of European descent in the ARIC Study. Model 1, represented by the solid line, includes age, age², and sex ($\text{AUC} = 0.515$, $P = 0.023$ for difference from $\text{AUC}_{\text{null}} = 0.50$). Model 2, represented by the dashed line, includes age, age², sex, and the $n = 32$ confirmed BMI SNPs ($\text{AUC} = 0.0575$, $P < 10^{-5}$ for difference from $\text{AUC}_{\text{null}} = 0.50$). The difference between both AUCs is significant ($P < 10^{-4}$).




Figure 3. Regional plots of selected replicating BMI loci with missense and CNV variants SNPs are plotted by position on chromosome against association with BMI ($-\log_{10} P$ -value). The SNP name shown on the plot was the most significant SNP after stage 1 meta-analysis. Estimated recombination rates (from HapMap) are plotted in cyan to reflect the local LD structure. The SNPs surrounding the most significant SNP are color-coded to reflect their LD with this SNP (taken from pairwise r^2 values from the HapMap CEU database, www.hapmap.org). Genes, position of exons, and direction of transcription from UCSC genome browser (<http://genome.ucsc.edu>) are noted. Hashmarks represent SNP positions available in the meta-analysis. (a, b, c) Missense variants noted with their amino acid change for the gene noted above the plot. (d) Structural haplotypes and BMI association signal in the *GPRC5B* region. A 21 kb deletion polymorphism is associated with 4 SNPs ($r^2=1.0$) that comprise the best haplogroup associating with BMI. Plots were generated using LocusZoom (<http://csg.sph.umich.edu/locuszoom>).




Figure 4. Phenotypic variance explained by common variants

(a) Variance explained is higher when SNPs not reaching genome-wide significance are included in the prediction model. The y-axis represents the proportion of variance explained at different P -value thresholds from stage 1 meta-analysis. Results are given for three studies (RSII, RSIII, QIMR), which were not included in the meta-analysis, after exclusion of all samples from The Netherlands (for RSII and RSIII) and the United Kingdom (for QIMR) from the discovery analysis for this sub-analysis. The dotted line represents the weighted average of the explained variance of three validation sets. (b) Cumulative number of susceptibility loci expected to be discovered, including those we have already identified and others that have yet to be detected, by the expected percentage of phenotypic variation explained and sample size required for a one-stage GWA study assuming a GC correction is utilized. The projections are based on loci that achieved a significance level of $P < 5 \times 10^{-8}$ in the joint analysis of stage 1 and stage 2 and the distribution of their effect sizes in stage 2. The dotted red line corresponds to the expected phenotypic variance explained by the 22 loci that are expected to be discovered in a one-stage GWAS with the sample size of stage 1 of this study.




Figure 5. Second signal at the MC4R locus contributing to BMI
 SNPs are plotted by position in a 1 Mb window of chromosome 18 against association with BMI ($\log_{10} P$ -value). Panel (a) highlights the most significant SNP in stage 1 meta-analysis, panel (b) the most significant SNP after conditional analysis where the model included the most strongly associated SNP from panel A as a covariate. Estimated recombination rates (from HapMap) are plotted in cyan to reflect the local LD structure. The SNPs surrounding the most significant SNP are color-coded to reflect their LD with this SNP (taken from pairwise r^2 values from the HapMap CEU database, www.hapmap.org). Genes, exons, and direction of transcription from UCSC genome browser (genome.ucsc.edu) are noted. Hashmarks at the top of the figure represent positions of SNPs in the meta-analysis. Regional plots were generated using LocusZoom (<http://csg.sph.umich.edu/locuszoom>).

Table 1

Stage 1 and stage 2 results of the 32 SNPs that were associated with BMI at genome-wide significance ($P < 5.10^{-8}$) levels.

SNP	Nearest gene	Other nearby genes*	Chr	Position** (bp)	Alleles** Effect Other	Frequency effect allele (%)	Per allele change in BMI beta (se)***	Explained variance (%)	Stage 1 P-value	Stage 2 P-value	Stage 1 + 2 n	P-value
Previous BMI loci												
rs1558902	<i>FTO</i>		16	52,361,075	a t	42%	0.39 (0.02)	0.34%	2.05E-62	1.007E-60	192,344	4.8E-120
rs2867125	<i>TMEM18</i>		2	612,827	c t	83%	0.31 (0.03)	0.15%	2.42E-22	4.42E-30	197,806	2.77E-49
rs571312	<i>MC4R B</i>		18	55,990,749	a c	24%	0.23 (0.03)	0.10%	1.82E-22	3.19E-21	203,600	6.43E-42
rs10938397	<i>GNPDA2</i>		4	44,877,284	g a	43%	0.18 (0.02)	0.08%	4.35E-17	1.45E-15	197,008	3.78E-31
rs10767664	<i>BDNF B,M</i>		11	27,682,562	a t	78%	0.19 (0.03)	0.07%	5.53E-13	1.17E-14	204,158	4.69E-26
rs2815752	<i>NEGR1 C,Q</i>		1	72,585,028	a g	61%	0.13 (0.02)	0.04%	1.17E-14	2.29E-09	198,380	1.61E-22
rs7359397	<i>SH2B1 Q,B,M</i>	<i>APOB48R Q,M, SULT1A2 Q,M, AC138894.2 M, ATXN2 L M, TUFM Q</i>	16	28,793,160	t c	40%	0.15 (0.02)	0.05%	1.75E-10	7.89E-12	204,309	1.88E-20
rs9816226	<i>ETV5</i>		3	187,317,193	t a	82%	0.14 (0.03)	0.03%	7.61E-14	1.15E-06	196,221	1.69E-18
rs3817334	<i>MTCH2 Q,M</i>	<i>NDUFSS Q, CUGBP1 Q</i>	11	47,607,569	t c	41%	0.06 (0.02)	0.01%	4.79E-11	1.10E-03	191,943	1.59E-12
rs29941	<i>KCTD15</i>		19	39,001,372	g a	67%	0.06 (0.02)	0.00%	1.31E-09	2.40E-02	192,872	3.01E-09
Previous waist & weight loci												
rs543874	<i>SEC16B</i>		1	176,156,103	g a	19%	0.22 (0.03)	0.07%	1.66E-13	2.41E-11	179,414	3.56E-23
rs987237	<i>TFAP2B</i>		6	50,911,009	g a	18%	0.13 (0.03)	0.03%	5.97E-16	2.40E-06	195,776	2.90E-20
rs7138803	<i>FAIM2</i>		12	48,533,735	a g	38%	0.12 (0.02)	0.04%	3.96E-11	7.82E-08	200,064	1.82E-17
rs10150332	<i>NRXN3</i>		14	79,006,717	c t	21%	0.13 (0.03)	0.02%	2.03E-07	2.86E-05	183,022	2.75E-11
Newly identified BMI loci												
rs713586	<i>RBJ</i>	<i>ADCY3 Q, M, POMC Q, B</i>	2	25,011,512	c t	47%	0.14 (0.02)	0.06%	1.80E-07	1.44E-16	230,748	6.17E-22
rs12444979	<i>GPRC5B C, Q</i>	<i>IQCK Q</i>	16	19,841,101	c t	87%	0.17 (0.03)	0.04%	4.20E-11	8.13E-12	239,715	2.91E-21
rs2241423	<i>MAP2K5</i>	<i>LBOXCOR1 M</i>	15	65,873,892	g a	78%	0.13 (0.02)	0.03%	1.15E-10	1.59E-09	227,950	1.19E-18
rs2287019	<i>QPCTL</i>	<i>GIPR B, M</i>	19	50,894,012	c t	80%	0.15 (0.03)	0.04%	3.18E-07	1.40E-10	194,564	1.88E-16
rs1514175	<i>TNN13 K</i>		1	74,764,232	a g	43%	0.07 (0.02)	0.02%	1.36E-09	7.04E-06	227,900	8.16E-14
rs13107325	<i>SLC39A8 Q, M</i>		4	103,407,732	t c	7%	0.19 (0.04)	0.03%	1.37E-07	1.93E-07	245,378	1.50E-13
rs2112347	<i>FLJ35779 M</i>	<i>HMGCR B</i>	5	75,050,998	t g	63%	0.10 (0.02)	0.02%	4.76E-08	8.29E-07	231,729	2.17E-13

SNP	Nearest gene	Other nearby genes*	Chr	Position** (bp)	Alleles** Effect Other	Frequency effect allele (%)	Per allele change in BMI beta (se)***	Explained variance (%)	Stage 1 P-value	Stage 2 P-value	Stage 1 + 2 n	P-value
rs10968576	<i>LRRN6C</i>		9	28,404,339	g a	31%	0.11 (0.02)	0.02%	1.88E-08	3.19E-06	216,916	2.65E-13
rs3810291	<i>TMEM160 Q</i>	<i>ZC3H4 Q</i>	19	52,260,843	a g	67%	0.09 (0.02)	0.02%	1.04E-07	1.59E-06	233,512	1.64E-12
rs887912	<i>FANCL</i>		2	59,156,381	t c	29%	0.10 (0.02)	0.03%	2.69E-06	1.72E-07	242,807	1.79E-12
rs13078807	<i>CADM2</i>		3	85,966,840	g a	20%	0.10 (0.02)	0.02%	9.81E-08	5.32E-05	237,404	3.94E-11
rs11847697	<i>PRKDI</i>		14	29,584,863	t c	4%	0.17 (0.05)	0.01%	1.11E-08	2.25E-04	241,667	5.76E-11
rs2890652	<i>LRPIB</i>		2	142,676,401	c t	18%	0.09 (0.03)	0.02%	2.38E-07	9.47E-05	209,068	1.35E-10
rs1555543	<i>PTBP2</i>		1	96,717,385	c a	59%	0.06 (0.02)	0.01%	7.65E-07	4.48E-05	243,013	3.68E-10
rs4771122	<i>MTIF3</i>	<i>GTF3A Q</i>	13	26,918,180	g a	24%	0.09 (0.03)	0.02%	1.20E-07	8.24E-04	198,577	9.48E-10
rs4836133	<i>ZNF608</i>		5	124,360,002	a c	48%	0.07 (0.02)	0.01%	7.04E-07	1.88E-04	241,999	1.97E-09
rs4929949	<i>RPL27A</i>	<i>TUB B</i>	11	8,561,169	c t	52%	0.06 (0.02)	0.01%	7.57E-08	1.00E-03	249,791	2.80E-09
rs206936	<i>NUDT3</i>	<i>HMGAI B</i>	6	34,410,847	g a	21%	0.06 (0.02)	0.01%	2.81E-06	7.39E-04	249,777	3.02E-08

* Genes within +/- 500 kb of the lead SNP

** Positions according to Build 36 and allele coding based on the positive strand

*** Effect sizes in kg/m2 obtained from Stage 2 cohorts only

Q Association and eQTL data converge to affect gene expression

B Biological candidate

M BMI-associated variant is in strong LD ($r^2 > 0.75$) with a missense variant in the indicated gene

C CNV